MARKETS / BALCAO / PETV
BALCAO · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

PetVivo Holdings, Inc. PETV

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.1M
▲ 0.8% vs FY2024
EPS · FY25
$-0.38
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-326.3%
Net margin · FY25
-917.4%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.1M
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.00040.00080.00120.0-0.0200920122016201920222025
0.00040.00080.00120.0-0.02016201920222025

The company lost 917 cents on every revenue dollar this year.

Per share
USD -0.38
Diluted EPS, FY2025
EPS
0.40.81.2-0.38200920122016201920222025
0.40.81.2-0.382016201920222025

The company pays no cash dividend.

Profitability
-326.3%
Return on equity, FY2025
ROE
0.250.50.751-326.3%200920122016201920222025
0.250.50.751-326.3%2016201920222025
Operating margin-793.9%
Net margin-917.4%
Return on assets-162.2%

Each USD of equity lost 326 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+146.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+7.6%
+146.4%
+31.3%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.110.04200920122016201920222025
0.010.042016201920222025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.6M
total assets, end of FY2025
Total assetsUSD 3.6M
EquityUSD 2.2M
Gross debtUSD 321,447.00
Current ratio1.35×

Equity funds 61% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2012
2011
2010
2009
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
·
·
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.38
−0.41
−0.78
−0.85
·
−0.57
−0.39
−0.26
−0.14
−1.73
−0.46
−0.21
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−326.3
−342.5
−1552.9
−259.8
−197.1
·
·
·
−488.8
−4409.2
−10405.6
−970.9
·
·
·
·
Shares out B
0.04
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.02
0.01
0.01
0.01
0.19
0.11
0.11
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
50 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 1 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed